Shares of Artivion, Inc. (NYSE:AORT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $47.8333.
Several research analysts have weighed in on AORT shares. Citizens Jmp dropped their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Friday, April 10th. Needham & Company LLC dropped their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday, March 5th.
Read Our Latest Analysis on Artivion
Artivion Stock Down 0.6%
Artivion (NYSE:AORT – Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.55% and a return on equity of 7.15%. The company’s quarterly revenue was up 19.2% on a year-over-year basis. On average, research analysts predict that Artivion will post 0.5 EPS for the current fiscal year.
Insider Buying and Selling
In other Artivion news, CAO Amy Horton sold 901 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the completion of the sale, the chief accounting officer directly owned 139,088 shares of the company’s stock, valued at $5,254,744.64. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the completion of the sale, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. This represents a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 133,043 shares of company stock valued at $4,977,158. 6.30% of the stock is owned by company insiders.
Institutional Trading of Artivion
Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in Artivion by 578.4% in the fourth quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock worth $1,780,000 after acquiring an additional 33,277 shares in the last quarter. Public Sector Pension Investment Board grew its position in Artivion by 23.7% in the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after acquiring an additional 30,989 shares in the last quarter. JPMorgan Chase & Co. grew its position in Artivion by 338.2% in the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after acquiring an additional 94,312 shares in the last quarter. Kennedy Capital Management LLC grew its position in Artivion by 19.0% in the third quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after acquiring an additional 70,030 shares in the last quarter. Finally, Champlain Investment Partners LLC bought a new stake in shares of Artivion during the 3rd quarter worth $17,912,000. 86.37% of the stock is owned by institutional investors.
Artivion Company Profile
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Featured Stories
- Five stocks we like better than Artivion
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
